RxDoctor Payments Data

Francisco Quijas

Geriatric Medicine · Los Angeles, CANPI 1659445823

Payments from drug & device makers

$925in general payments, 2019–2025

Across 44 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$132
  • Lilly USA, LLC$128
  • Pfizer$111
  • Novartis$83
  • Merck$75
  • Sunovion Pharmaceuticals Inc.$71
  • plus $324 from 11 others

What the payments were for

  • Food & beverage$925100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$925 in reported general payments places this provider in the 75th percentile of 494 geriatric medicine providers in California.

See all geriatric medicine providers in California

Medicare billing

Part B allowed, 2024
$117,175
Medicare patients
254
Services billed
1,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin116$109,842
JanuviaSitagliptin Phosphate84$95,716
TrulicityDulaglutide68$82,437
OzempicSemaglutide81$77,101
EliquisApixaban101$73,125
TradjentaLinagliptin35$44,155
XareltoRivaroxaban23$26,538
EntrestoSacubitril/Valsartan30$23,839
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog100$20,604
FarxigaDapagliflozin Propanediol23$20,395
BrilintaTicagrelor20$11,338
Lantus SolostarInsulin Glargine,hum.Rec.Anlog123$10,783
LinzessLinaclotide11$10,751
Atorvastatin Calcium769$5,582
Soliqua 100-33Insulin Glargine/Lixisenatide11$4,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$27$153,997151 claims
MerckJanuvia$75$95,71684 claims
Lilly USA, LLCTrulicity$128$82,43768 claims
Novo NordiskOzempic$19$77,10181 claims
PfizerEliquis$111$73,125101 claims
AstraZenecaFarxiga, Brilinta$24$31,73443 claims
NovartisEntresto$83$23,83930 claims
AbbVieLinzess$29$10,75111 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$45$5,81627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 494 geriatric medicine providers in California.

Other geriatric medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →